Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betrixaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 17/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betrixaban SCHEMBL29374026 | 1.00 | F10 (1.00) | F10KCNH2F2 | |
| Betrixaban SCHEMBL29858125 | 0.99 | F10 (0.98) | F10KCNH2F2 | |
| Betrixaban SCHEMBL20587589 | 0.95 | F10 (0.90) | F10KCNH2F2 | |
| Betrixaban SCHEMBL20587587 | 0.95 | F10 (0.90) | F10KCNH2F2 | |
| SCHEMBL765235 | 0.92 | F10 (0.85) | F10KCNH2F2 | |
| SCHEMBL22136974 | 0.91 | F10 (0.83) | F10KCNH2F2 | |
| SCHEMBL10063542 | 0.90 | F10 (0.88) | F10KCNH2F2 | |
| SCHEMBL891008 | 0.90 | KCNH2 (0.86) | F10KCNH2F2 | |
| SCHEMBL254416 | 0.90 | F10 (0.82) | F10KCNH2F2 | |
| SCHEMBL1286409 | 0.90 | F10 (1.00) | F10KCNH2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390467-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2024-11-28 | — | — | US | claimed |
| US-11357836-B2 | Prohemostatic proteins for the treatment of bleeding | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2022-06-14 | — | — | US | claimed |
| US-11304995-B2 | Prohemostatic proteins for the treatment of bleeding | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2022-04-19 | — | — | US | claimed |
| EP-3744840-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | Academisch Ziekenhuis Leiden (NL) | 2020-12-02 | — | — | EP | claimed |
| EP-3149163-B1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2020-06-03 | — | — | EP | claimed |
| US-20200138916-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2020-05-07 | — | — | US | claimed |
| US-20200138917-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2020-05-07 | — | — | US | claimed |
| US-10537618-B2 | Prohemostatic proteins for the treatment of bleeding | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2020-01-21 | — | — | US | claimed |
| US-20170157223-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN | 2017-06-08 | — | — | US | claimed |
| EP-3149163-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | Academisch Ziekenhuis Leiden (NL) | 2017-04-05 | — | — | EP | claimed |
| WO-2015183085-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2015-12-03 | — | — | WO | claimed |
| EP-3788039-B1 | FACTOR XIIA INHIBITORS | UNIV LEEDS INNOVATIONS LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-20240390467-A1 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2024-11-28 | — | — | US | disclosed |
| US-12083170-B2 | Prohemostatic proteins for the treatment of bleeding | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2024-09-10 | — | — | US | disclosed |
| WO-2007056517-A2 | PHARMACEUTICAL SALTS AND POLYMORPHS OF N- (5-CHL0R0-2-PYRIDINYL) -2- [ [4- [ (DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO] -5-METH OXY-BENZAMIDE, A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112039-A1 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | MILLENNIUM PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112039-A1 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | MILLENNIUM PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112039-A1 | Better thermal and hydrolytic stability than the free-base compounds; N-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide Hydrochloride | F12, CMA1, F11 | F10 10/4885KCNH2 741/4885F2 19/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | F10 18/4885KCNH2 1101/4885F2 1/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | F10 12/4885KCNH2 1899/4885F2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.